|Study Description:||The goal of this clinical research study is to learn about the safety of giving |
CLT-008 to patients receiving chemotherapy for leukemia or MDS.
CLT-008 is made from the blood cells of healthy donors. It is designed to
temporarily replace a type of your white blood cells, which may help lower the
risk of infection while your white blood cell count is low (usually about 2-3
weeks after chemotherapy).
Neupogen® (filgrastim, G-CSF) is designed to help lower the risk of infection
by increasing your white blood cell count.